Assembly Biosciences Completes $115 Million Stock and Warrant Offering With Full Underwriters Option Exercise

Assembly Biosciences (Nasdaq:
ASMB) has completed its underwritten public offering of common stock and pre‑funded warrants, including full exercise of the underwriters’ option to purchase additional shares, raising approximately $115.0 million in gross proceeds and about $107.4 million in net proceeds after underwriting discounts, commissions, and estimated expenses.

The offering consisted of 3,358,602 shares of common stock at $26.50 per share, pre‑funded warrants to purchase up to 415,000 additional shares at $26.499 per warrant, and 566,040 additional shares purchased in full by the underwriters exercising their 30‑day option.

The company plans to use the proceeds primarily to fund clinical development of its pipeline candidates (including programs targeting serious viral and liver diseases) and for general corporate purposes.

Executive officers and directors have entered into customary 90‑day lock‑up arrangements, and the securities were offered pursuant to a shelf registration statement filed with the SEC.